POINT Biopharma Global (NASDAQ:PNT) Price Target Increased to $11.00 by Analysts at Raymond James

POINT Biopharma Global (NASDAQ:PNT – Get Rating) had its price target lifted by Raymond James from $10.00 to $11.00 in a research note issued to investors on Tuesday, BayStreet.CA reports. The firm currently has an outperform rating on the stock.

Other analysts have also recently issued reports about the company. Piper Sandler lowered their target price on POINT Biopharma Global from $17.00 to $14.00 in a research report on Monday, November 14th. SVB Leerink assumed coverage on POINT Biopharma Global in a report on Wednesday, November 30th. They set an outperform rating and a $14.00 price objective for the company. Oppenheimer cut their target price on POINT Biopharma Global to $15.00 in a report on Thursday, November 17th. Finally, Truist Financial lowered their price target on POINT Biopharma Global from $22.00 to $14.00 and set a buy rating on the stock in a research report on Tuesday, November 15th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, POINT Biopharma Global has an average rating of Buy and an average price target of $16.25.

POINT Biopharma Global Stock Performance

Shares of NASDAQ PNT opened at $7.72 on Tuesday. POINT Biopharma Global has a 1 year low of $5.22 and a 1 year high of $10.98. The firm’s 50 day moving average price is $7.46 and its 200 day moving average price is $7.78. The firm has a market cap of $803.11 million, a P/E ratio of -8.87 and a beta of 0.14.

Hedge Funds Weigh In On POINT Biopharma Global

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PFM Health Sciences LP bought a new position in POINT Biopharma Global during the third quarter worth $34,903,000. BVF Inc. IL raised its position in POINT Biopharma Global by 66.0% in the third quarter. BVF Inc. IL now owns 5,590,048 shares of the company’s stock worth $43,211,000 after acquiring an additional 2,222,222 shares during the period. State Street Corp raised its position in shares of POINT Biopharma Global by 721.6% in the second quarter. State Street Corp now owns 2,217,796 shares of the company’s stock valued at $15,103,000 after purchasing an additional 1,947,859 shares during the period. Point72 Asset Management L.P. grew its stake in POINT Biopharma Global by 4,523.4% during the second quarter. Point72 Asset Management L.P. now owns 1,954,229 shares of the company’s stock valued at $13,308,000 after acquiring an additional 1,911,961 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in POINT Biopharma Global by 124.4% in the 1st quarter. Vanguard Group Inc. now owns 3,200,215 shares of the company’s stock worth $25,506,000 after buying an additional 1,774,040 shares in the last quarter. Institutional investors own 72.77% of the company’s stock.

About POINT Biopharma Global

(Get Rating)

POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.